1. Scrip
  2. >>R&D
  3. >>Clinical Trials

'Pharma Fireworks': Pipeline Catalysts To Watch Out For In Q2

 
• By Sten Stovall

Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.

Fireworks
Pipeline Catalysts Viewed In BioMedTracker Q2 2019 Outlook Report • Source: Shutterstock

GlaxoSmithKline's multiple myeloma candidate, Scynexis's treatment for invasive candidiasis caused by the emerging global health threat Candida auris, and Takeda/Shire's maribavir for cytomegalovirus in transplant patients are among pipeline drugs expected to report important clinical data before the end of June, according to Biomedtracker's latest quarterly overview of coming key catalysts in the next three months for novel therapies.

Highlighted drugs awaiting an approval decision in the quarter include AMAG's bremelanotide for female sexual arousal disorder and Nektar Therapeutics'...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.